초록 ▼

The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to for

The present invention provides an extended release oral dosage form of prodrugs of gabapentin and other GABA analogs, which dosage forms exhibit reduced toxicity. The dosage forms are particularly useful in administering those prodrugs of gabapentin and other GABA analogs that are metabolized to form an aldehyde. The dosage forms of the invention are useful for treating or preventing diseases and/or disorders for which the parent gabapentin or other GABA analog are known to be therapeutically effective.

대표청구항 ▼

1. A method of reducing toxicity of an orally administered therapeutic GABA analog, comprising:formulating the GABA analog as a prodrug comprised of the therapeutic GABA analog covalently bound to a cleavable promoiety;placing the prodrug in a sustained release oral dosage form;introducing the dosag

1. A method of reducing toxicity of an orally administered therapeutic GABA analog, comprising:formulating the GABA analog as a prodrug comprised of the therapeutic GABA analog covalently bound to a cleavable promoiety;placing the prodrug in a sustained release oral dosage form;introducing the dosage form into the intestinal lumen of a patient by having the patient swallow the dosage form;releasing the prodrug gradually into the intestinal lumen of the patient over a period of hours; andcleaving the promoiety from the prodrug to provide a therapeutic concentration of the GABA analog in the plasma of the patient, wherein the dosage form releases from 0 to 20% of the prodrug in 0 to 2 hours, from 20 to 50% of the prodrug in 2 to 12 hours, from 50 to 85% of the prodrug in 3 to 20 hours and greater than 75% of the prodrug in 5 to 18 hours. 2. The method of claim 1, wherein the toxicity of the GABA analog administered from said sustained release oral dosage form is less than the toxicity of an equivalent dose of the GABA analog administered from an immediate release oral dosage form. 3. The method of claim 1, wherein the toxicity of the promoiety administered from said sustained oral release dosage form, and any metabolites thereof, is less than the toxicity of the promoiety, and any metabolites thereof, administered at an equivalent dose from an immediate release oral dosage form. 4. The method of any of claims 1 to 3, wherein the promoiety metabolizes to form an aldehyde. 5. The method of claim 4, wherein the aldehyde comprises formaldehyde. 6. The method of any one of claims 1 to 3, wherein the promoiety metabolizes to form an acid that depletes carnitine in said patient. 7. The method of claim 6, wherein the acid comprises pivalic acid. 8. The method of claim 1, wherein the period of hours comprises at least about 6 hours. 9. The method of claim 1, wherein the period of hours comprises at least about 8 hours. 10. The method of claim 1, wherein the period of hours comprises at least about 12 hours. 11. The method of claim 1, wherein the concentration of the GABA analog in plasma of the patient over time provides a curve of concentration of the GABA analog in the plasma over time, the curve having an area under the curve (AUC) which is proportional to the dose of GABA analog administered. 12. The method of claim 11, wherein the curve has a maximum plasma concentration (C max ) which is proportional to the dose of GABA analog administered. 13. The method of any one of claims 1 , 11 or 12 , wherein the C max is less than 75% of the C max obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form, and the AUC is at least 50% of the AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form. 14. The method of any one of claims 1 , 11 or 12 , wherein the C max is less than 60% of the C max obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form, and the AUC is at least 75% of the AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form. 15. The method of claim 13, wherein the AUC is substantially the same as the AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form. 16. The method of claim 14, wherein the AUC is substantially the same as the AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form. 17. A method of orally administering a GABA analog prodrug, comprising:formulating the GABA analog as a prodrug comprised of the therapeutic GABA analog covalently bound to a cleavable promoiety;placing the prodrug in a sustained release oral dosage form;introducing the dosage form into the intestinal lumen of a patient by having the patient swallow the dosage form;releasing the prodrug gradually from the swallowed dosage form into th e intestinal lumen of the patient over a period of hours; andallowing the GABA analog to be cleaved from the promoiety after said swallowing to provide a therapeutic concentration of the GABA analog in the plasma of the patient wherein the dosage form releases from 0 to 20% of the prodrug in 0 to 2 hours, from 20 to 50% of the prodrug in 2 to 12 hours, from 50 to 85% of the prodrug in 3 to 20 hours and greater than 75% of the prodrug in 5 to 18 hours. 18. The method of claim 17, wherein the promoiety metabolizes to form an aldehyde. 19. The method of claim 18, wherein the aldehyde comprises formaldehyde. 20. The method of claim 17, wherein the promoiety metabolizes to form an acid that depletes carnitine in said patient. 21. The method of claim 17, wherein the period of hours comprises at least about 6 hours. 22. The method of claim 17, wherein the period of hours comprises at least about 8 hours. 23. The method of claim 17, wherein the period of hours comprises at least about 12 hours. 24. The method of claim 17, wherein the concentration of the GABA analog in plasma of the patient over time provides a curve of concentration of the GABA analog in the plasma over time, the curve having an area under the curve (AUC) which is proportional to the dose of GABA analog administered. 25. The method of claim 17, wherein the curve has a maximum plasma concentration (C max ) which is proportional to the dose of GABA analog administered. 26. The method of claim 24 or 25, wherein the C max is less than 75% of the C max obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form and the AUC is at least 50% of an AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form. 27. The method of claim 24 or 25, wherein the C max is less than 60% of the C max obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form and the AUC is at least 75% of an AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form. 28. The method of claim 26, wherein the AUC is substantially the same as the AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form. 29. The method of claim 27, wherein the AUC is substantially the same as the AUC obtained from administering an equivalent dose of the prodrug from an immediate release oral dosage form.